# PRevention Using EPA Against coloREctal Cancer

> **NCT04216251** · PHASE1,PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 81 (actual)

## Conditions studied

- Colorectal Adenoma
- Colorectal Cancer
- Endoscopic Surgery
- Eicosapentaenoic Acid
- Gastrointestinal Microbiome

## Interventions

- **DRUG:** AMR101

## Key facts

- **NCT ID:** NCT04216251
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-09
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2024-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04216251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04216251, "PRevention Using EPA Against coloREctal Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04216251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*